title: 48-week RESIST data confirms TPV benefit.
authors.forename: Chris
authors.initials: C
authors.lastname: Gadd
mesh_terms: D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D011753:Pyrones / Q000627:therapeutic use*; D013449:Sulfonamides; D019562:Viral Load
chemical_list: D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; C107201:tipranavir